Key result
Bariatric surgery significantly increased median adiponectin levels from 4,346 to 8,973 ng/mL and reduced hypoadiponectinemia prevalence from 90% to 35% at 6 months in patients with morbid obesity.
Why the study?
Does bariatric surgery improve biochemical markers of arterial remodeling in female patients with morbid obesity?
Cohort (n=55)
Does bariatric surgery improve biochemical markers of arterial remodeling in female patients with morbid obesity?
Absolute Event Rate: 8972.87% vs 4345.94%
p-value: p=<0.0001
Bariatric surgery in morbidly obese patients significantly improves biochemical markers of arterial remodeling, including adiponectin, MMP-2, and MMP-9, suggesting a reduction in cardiovascular risk.
Bariatric surgery may raise adiponectin in morbid obesity; hypothesis-generating for arterial remodeling benefits, needs prospective trials before practice change.
OBJECTIVE: The objective of this study was to assess the emerging biochemical markers of arterial remodeling in patients with morbid obesity before and after surgical treatment and to compare the results to a control group. MATERIAL AND METHODS: The prospective study included 40 patients with BMI 47.73 ± 6.18 kg/m(2), qualified for elective bariatric surgery and re-examined 6 months after the surgery. The control group consisted of non obese, age and sex matched 15 subjects. Following laboratory examinations were performed in all patients: basic laboratory examinations, MMP-2, MMP-9, adiponectin, PAI-1, CD40L, E-selectin. RESULTS: Examination of patients 6 m after bariatric surgery revealed a 34.57 ± 9.71 reduction in excess body weight. Comparison of the study group at two time points revealed differences in adiponectin, MMP-2 and MMP-9 levels. Hypoadiponectinemia was observed in 35 % patients 6 months after bariatric surgery compared to 90 % patients before the surgery. In addition, a strong correlation was observed between body fat mass and adiponectin levels (r = -0.504, p = 0.055). Moderate correlations were demonstrated between E-selectin levels and BMI (r = 0.361; p = 0.022), and metalloproteinase-9 levels (r = 0.326; p = 0.040). In addition, strong relationship was demonstrated between MMP-2 and MMP-9 (r = 0.502; p = 0.001), and moderate between MMP-2 and adiponectin levels (r = 0.449; p = 0.003). MMP-9 levels were moderately correlated with HDL-cholesterol levels (r = 0.316; p = 0.046). CONCLUSIONS: Assessment of laboratory markers of arterial remodeling and metabolism suggest their adverse changes in patients with morbid obesity. However, body mass reduction due to bariatric surgery decreases inflammatory status, improves biochemical markers of arterial remodeling as well as to beneficial changes in the metabolism.
No takes yet. Share an insight, caveat, or question.
Domienik‐Karłowicz et al. (2014) conducted a cohort in Morbid obesity (n=55). Bariatric surgery (gastric bypass) vs. Baseline (pre-surgery) was evaluated on Median adiponectin levels (ng/mL) (p=<0.0001). Bariatric surgery significantly increased median adiponectin levels from 4,346 to 8,973 ng/mL and reduced hypoadiponectinemia prevalence from 90% to 35% at 6 months in patients with morbid obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: